Olema Pharmaceuticals, Inc. (OLMA)

9.90 -0.81 (-7.56%) At close: 04:00PM EDT

Olema Pharmaceuticals, Inc.

780 Brannan Street
San Francisco, CA 94103
United States
415-651-3316
https://olema.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 74

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sean P. Bohen M.D., Ph.D.	President, CEO & Director	1M	N/A	1967
Mr. Shane William Charles Kovacs M.B.A.	Chief Operating & Financial Officer	726.17k	N/A	1974
Dr. Naseem Zojwalla M.D.	Chief Medical Officer	775.48k	N/A	1973
Mr. Geoffrey Mogilner	Vice President of Investor Relations & Communications	N/A	N/A	N/A
Ms. Julie Dexter	Senior VP & Head of People	N/A	N/A	N/A
Dr. David C. Myles Ph.D.	Chief Discovery & Non-Clinical Development Officer	200k	N/A	1963
Ms. Demiana Faltaos Ph.D., Pharm.D.	VP & Head of Clinical Pharmacology	N/A	N/A	N/A
Mr. John B. Moriarty Jr., J.D.	Corporate Secretary	434.32k	N/A	1968
Ms. Sasha Austin CPA	VP of Finance & Controller	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Corporate governance

Olema Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.